Therapeutic opportunities from tumour biology in metastatic colon cancer

H L McLeod, J A McKay, Elaina Susan Renata Collie-Duguid, J Cassidy

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Tumour metastasis is the major cause of morbidity and mortality from colorectal cancer. While improvements in duality of life and patient survival have been made over the past 10 years, the majority of patients with metastatic colorectal cancel will die from their disease. As knowledge of the biology of colon cancer and its invasion/metastasis programme evolve, this presents new therapeutic opportunities for pharmacological and genetic intervention. This review discusses the current approaches to metastatic colorectal cancer therapy, details genomic and biological variance between primary and metastatic tumours, and highlights approaches for harnessing these differences to improve therapy. (C) 2000 Elsevier Science Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)1706-1712
Number of pages7
JournalEuropean Journal of Cancer
Volume36
Publication statusPublished - 2000

Keywords

  • colorectal cancer
  • metastasis
  • developmental therapeutics
  • gene therapy
  • RECOMBINANT VACCINIA VIRUS
  • CYTOSINE DEAMINASE GENE
  • herpes simplex virus
  • CARCINOEMBRYONIC ANTIGEN PROMOTER
  • comparative genomic hybridization
  • THYMIDYLATE SYNTHASE GENE
  • wild type P53
  • liver metastases
  • lung cancer

Cite this

Therapeutic opportunities from tumour biology in metastatic colon cancer. / McLeod, H L ; McKay, J A ; Collie-Duguid, Elaina Susan Renata; Cassidy, J .

In: European Journal of Cancer, Vol. 36, 2000, p. 1706-1712.

Research output: Contribution to journalArticle

@article{213509b8e950465dbd45c1cf30efd435,
title = "Therapeutic opportunities from tumour biology in metastatic colon cancer",
abstract = "Tumour metastasis is the major cause of morbidity and mortality from colorectal cancer. While improvements in duality of life and patient survival have been made over the past 10 years, the majority of patients with metastatic colorectal cancel will die from their disease. As knowledge of the biology of colon cancer and its invasion/metastasis programme evolve, this presents new therapeutic opportunities for pharmacological and genetic intervention. This review discusses the current approaches to metastatic colorectal cancer therapy, details genomic and biological variance between primary and metastatic tumours, and highlights approaches for harnessing these differences to improve therapy. (C) 2000 Elsevier Science Ltd. All rights reserved.",
keywords = "colorectal cancer, metastasis, developmental therapeutics, gene therapy, RECOMBINANT VACCINIA VIRUS, CYTOSINE DEAMINASE GENE, herpes simplex virus, CARCINOEMBRYONIC ANTIGEN PROMOTER, comparative genomic hybridization, THYMIDYLATE SYNTHASE GENE, wild type P53, liver metastases, lung cancer",
author = "McLeod, {H L} and McKay, {J A} and Collie-Duguid, {Elaina Susan Renata} and J Cassidy",
year = "2000",
language = "English",
volume = "36",
pages = "1706--1712",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "ELSEVIER APPL SCI PUBL LTD",

}

TY - JOUR

T1 - Therapeutic opportunities from tumour biology in metastatic colon cancer

AU - McLeod, H L

AU - McKay, J A

AU - Collie-Duguid, Elaina Susan Renata

AU - Cassidy, J

PY - 2000

Y1 - 2000

N2 - Tumour metastasis is the major cause of morbidity and mortality from colorectal cancer. While improvements in duality of life and patient survival have been made over the past 10 years, the majority of patients with metastatic colorectal cancel will die from their disease. As knowledge of the biology of colon cancer and its invasion/metastasis programme evolve, this presents new therapeutic opportunities for pharmacological and genetic intervention. This review discusses the current approaches to metastatic colorectal cancer therapy, details genomic and biological variance between primary and metastatic tumours, and highlights approaches for harnessing these differences to improve therapy. (C) 2000 Elsevier Science Ltd. All rights reserved.

AB - Tumour metastasis is the major cause of morbidity and mortality from colorectal cancer. While improvements in duality of life and patient survival have been made over the past 10 years, the majority of patients with metastatic colorectal cancel will die from their disease. As knowledge of the biology of colon cancer and its invasion/metastasis programme evolve, this presents new therapeutic opportunities for pharmacological and genetic intervention. This review discusses the current approaches to metastatic colorectal cancer therapy, details genomic and biological variance between primary and metastatic tumours, and highlights approaches for harnessing these differences to improve therapy. (C) 2000 Elsevier Science Ltd. All rights reserved.

KW - colorectal cancer

KW - metastasis

KW - developmental therapeutics

KW - gene therapy

KW - RECOMBINANT VACCINIA VIRUS

KW - CYTOSINE DEAMINASE GENE

KW - herpes simplex virus

KW - CARCINOEMBRYONIC ANTIGEN PROMOTER

KW - comparative genomic hybridization

KW - THYMIDYLATE SYNTHASE GENE

KW - wild type P53

KW - liver metastases

KW - lung cancer

M3 - Article

VL - 36

SP - 1706

EP - 1712

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -